



09-22-06

IFW

CASE ON/4-32326A

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV 727274268 US
Express Mail Label Number

September 21, 2006
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF

HEIKKI JOENSUU

INTERNATIONAL APPLICATION NO: PCT/EP03/00802

FILED: 27 JANUARY 2003

U.S. APPLICATION NO: 10/502,534

35 USC §371 DATE: 5 JANUARY 2005

FOR: TREATMENT OF RHEUMATOID ARTHRITIS USING IMATINIB

MS: Amendment

Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicant believes this paper is being filed before the mailing date of a first Office action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicant wishes to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

The asterisked references were cited in the International Search Report and since copies of said references were forwarded by the International Bureau, only copies of the non-asterisked references are enclosed. Also enclosed is a British Search Report, dated 8/22/02. The references cited therein were also listed in the International Search Report.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'Oona Jackson', written over a horizontal line.

Oona A. Jackson
Attorney for Applicant
Reg. No. 48,152

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-7852


Date: 9/21/06

ATTY. DOCKET NO.
ON/4-32326A
APPLICATION NO.
10/502,534
APPLICANT
Heikki Joensuu
FILING DATE
January 5, 2005

Group

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)



U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA	5,521,184	5/28/96	Zimmermann			
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AM	EP 0 564 409	10/06/93	Europe (English equivalent is U.S. Patent No. 5,521,184)			<input type="checkbox"/>	<input type="checkbox"/>
	AN	*WO 99/03854	01/28/99	WIPO			<input type="checkbox"/>	<input type="checkbox"/>
	AO	WO 01/00214	01/04/01	WIPO			<input type="checkbox"/>	<input type="checkbox"/>
	AP	WO 01/64200 A2	09/07/01	WIPO			<input type="checkbox"/>	<input type="checkbox"/>
	AQ	*WO 02/080925	10/17/02	WIPO			<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AR	Buchdunger et al., "Abl Protein-Tyrosine Kinase Inhibitor STI571 Inhibits In Vitro Signal Transduction Mediated by c-Kit and Platelet-Derived Growth Factor Receptors", <i>J Pharmacol Exper Thera</i> , Vol. 295, No. 1, pp. 139-145 (2000).
	AS	Cwynarski et al., "STI571 Inhibits the Activation and Proliferation of Normal T Lymphocytes", <i>Blood</i> , Vol. 98, No. 11, Pt. 2, pp. 256b-257b (2001) – Abstract #4757 – DERWENT No. 2002-17328 DRUGU P.
	AT	Deiningner, Goldman, Lydon and Melo, "The Tyrosine Kinase Inhibitor CGP 57148 Selectively Inhibits Hematopoietic Colony Formation by CML Progenitor Cells Over a 2-Log Dose Range", <i>Blood</i> , Vol. 88, No. 10, Suppl. 1, Pt. 1, p. 364a (1996) – Abstract #1444 – DERWENT No. 1997-07455 DRUGU P.

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Group

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	CA	*WO 02/083075	10/24/02	WIPO			<input type="checkbox"/>	<input type="checkbox"/>
	CB	*WO 02/092091	11/21/02	WIPO			<input type="checkbox"/>	<input type="checkbox"/>
	CC	WO 02/45717	06/13/02	WIPO			<input type="checkbox"/>	<input type="checkbox"/>
	CD	*WO 03/002108	01/09/03	WIPO			<input type="checkbox"/>	<input type="checkbox"/>
	CE	WO 03/002109	01/09/03	WIPO			<input type="checkbox"/>	<input type="checkbox"/>
	CF						<input type="checkbox"/>	<input type="checkbox"/>
	CG						<input type="checkbox"/>	<input type="checkbox"/>
	CH						<input type="checkbox"/>	<input type="checkbox"/>
	CI						<input type="checkbox"/>	<input type="checkbox"/>
	CJ						<input type="checkbox"/>	<input type="checkbox"/>
	CK						<input type="checkbox"/>	<input type="checkbox"/>
	CL						<input type="checkbox"/>	<input type="checkbox"/>
	CM						<input type="checkbox"/>	<input type="checkbox"/>
	CN						<input type="checkbox"/>	<input type="checkbox"/>
	CO						<input type="checkbox"/>	<input type="checkbox"/>
	CP						<input type="checkbox"/>	<input type="checkbox"/>
	CQ						<input type="checkbox"/>	<input type="checkbox"/>
	CR						<input type="checkbox"/>	<input type="checkbox"/>
	CS						<input type="checkbox"/>	<input type="checkbox"/>
	CT						<input type="checkbox"/>	<input type="checkbox"/>
	CU						<input type="checkbox"/>	<input type="checkbox"/>
	CV						<input type="checkbox"/>	<input type="checkbox"/>
	CW						<input type="checkbox"/>	<input type="checkbox"/>
	CX						<input type="checkbox"/>	<input type="checkbox"/>
	CY						<input type="checkbox"/>	<input type="checkbox"/>
	CZ						<input type="checkbox"/>	<input type="checkbox"/>

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
ON/4-32326A
APPLICATION NO.
10/502,534
APPLICANT
Heikki Joensuu
FILING DATE
January 5, 2005

Group

EXAMINER
INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	DA	Gilbert et al., "PDGF Signal Transduction Inhibition Ameliorates Mesangial Proliferative Glomerulonephritis", <i>J Am Soc Nephrol</i> , Vol. 11, p. 506A (2000) – Program #SU1131 (FC); Abstract #A2671 - BIOSIS No. 2002:252250 BIOSIS.
	DB	Gilbert et al., "PDGF Signal Transduction Inhibition Ameliorates Experimental Mesangial Proliferative Glomerulonephritis", <i>Kidney Int</i> , Vol. 59, No. 4, pp. 1324-1332 (2001).
	DC	Gordon et al., "The Tyrosine Kinase Inhibitor STI571 Preferentially Reduces the Capacity for Amplification of Granulocyte-Macrophage Progenitors (CFU-GM) from Patients With Chronic Myeloid Leukemia But Spares Normal CFU-GM", <i>Blood</i> , Vol. 94, No. 10, Suppl. 1, Pt. 1, p. 387a (1999) – Abstract #1718 – DERWENT No. 2000-15571 DRUGU P.
	DD	Marley et al., "The Tyrosine Kinase Inhibitor STI571, Like Interferon- α , Preferentially Reduces the Capacity for Amplification of Granulocyte-Macrophage Progenitors from Patients with Chronic Myeloid Leukemia", <i>Exp Hematol</i> , Vol. 28, No. 5, pp. 551-557 (2000).
	DE	Wang et al., "STI-571, a Selective Tyrosine Kinase Inhibitor, Significantly Enhances Antigen Presentation by Bone Marrow Derived APCs: Implications for Immunotherapy of Tumors-Derived from Antigen Presenting Cells", <i>Blood</i> , Vol. 98, No. 11, Pt. 1, p. 16a (2001) – Abstract #55, Poster Board #55-I – DERWENT No. 2002-138977 DRUGU P.
	DF	
	DG	
	DH	
	DI	
	DJ	
	DK	
	DL	
	DM	
	DN	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.